Clinical Trials Browser

Phase 3 × OTHER × letermovir × Clear all

NCT06449586 2025-12-15

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Phase 3 Active not recruiting

Other hematologic neoplasm

Hematologic Neoplasms